ArticleMedicine2017
Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: A case report and literature review.
Article in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06680401 (The Evaluation of Cytokines and Hormones as Biomarkers for Epithelioid Haemangioendothelioma and Generation of Patient-derived Preclinical Models to Assess the Activity of Anticancer Agents and Validate Novel Therapeutic Targets), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Evaluation of Cytokines and Hormones as Biomarkers for Epithelioid Haemangioendothelioma and Generation of Patient-derived Preclinical Models to Assess the Activity of Anticancer Agents and Validate Novel Therapeutic Targets
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Pathological complete remission of pulmonary epithelioid hemangioendothelioma: a case report and literature review.Journal of cardiothoracic surgery · 2026Review
- Clinical and pathological analysis of pulmonary epithelioid vascular endothelial tumor.Open life sciences · 2026Article
- Auricular epithelioid hemangioendothelioma: Two cases first diagnosed as auricular pseudocyst.Oncology letters · 2025Article
- Primary pulmonary epithelioid hemangioendothelioma.BMJ case reports · 2023Article
- New Molecular Insights, and the Role of Systemic Therapies and Collaboration for Treatment of Epithelioid Hemangioendothelioma (EHE).Current treatment options in oncology · 2023Review
- Primary malignant epithelioid hemangioendothelioma of the pleura: A review and report of a novel case.Clinical case reports · 2022Article
- Review
- Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature.Cancer medicine · 2021Review
- Effective combined therapy for pulmonary epithelioid hemangioendothelioma: A case report.World journal of clinical cases · 2020Article
- Multiple bilateral pulmonary epithelioid hemangioendothelioma mimicking metastatic lung cancer: case report and literature review.The Journal of international medical research · 2020Review
- Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?Therapeutics and clinical risk management · 2020Article
- [Research Progress of Pulmonary Epithelioid Hemangioendothelioma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Review
- Epithelioid Hemangioendothelioma as a Model of YAP/TAZ-Driven Cancer: Insights from a Rare Fusion Sarcoma.Cancers · 2018Review
- Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment.Current treatment options in oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationalePulmonary epithelioid hemangioendothelioma (P-EHE) is a rare tumor, with no established standard treatment. Overexpression of vascular endothelial growth factor receptor 2 (VEGFR-2) has been reported in some P-EHE patients. Apatinib, a new small molecule tyrosine kinase inhibitor that specifically targets VEGFR-2, has therapeutic benefits in some advanced tumors. However, its efficacy in P-EHE cases has not been reported. PATIENT CONCERNS: Herein, we presented a 44-year-old man with recurrent hemoptysis for approximately 9 years. DIAGNOSES: After hospitalization, relevant examinations were conducted. The disease was subsequently diagnosed as P-EHE.
interventionsThe patient underwent pulmonary lobectomy, but subsequently developed multiple metastases. Within the tumor, CD31, CK, and Vimentin were found to be positive, while CD34 was negative. Apatinib was initially administered 250 mg daily doses and after 1 month was increased to 500 mg daily. OUTCOMES: He showed noticeable symptomatic improvements and positive imaging changes in the first month of treatment. However, the disease progressed in the following month, despite the increased apatinib dose. LESSONS: Apatinib is possibly a new treatment for P-EHE. However, further clinical trials are necessary to confirm an effective dose and the efficacy and safety of apatinib in P-EHE treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.